During the past decade, Charleston Hematology Oncology Associates, Pa conducted 70 clinical trials. In the 10-year time frame, 70 clinical trials started and 60 clinical trials were completed, i.e. on average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 32 clinical trials started and 40 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Charleston Hematology Oncology Associates, Pa" #1 sponsor was "SWOG Cancer Research Network" with 15 trials, followed by "Bristol-Myers Squibb" with 13 trials sponsored, "Hoffmann-La Roche" with 10 trials sponsored, "Celgene" with 7 trials sponsored and "Gilead Sciences" with 7 trials sponsored. Other sponsors include 95 different institutions and companies that sponsored additional 65 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Charleston Hematology Oncology Associates, Pa" #1 collaborator was "National Cancer Institute (NCI)" with 19 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator, "ARMO BioSciences" with 2 trials as a collaborator, "Amgen" with 2 trials as a collaborator and "Merck Sharp & Dohme LLC" with 2 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "Charleston Hematology Oncology Associates, Pa" are "Breast Cancer" (13 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Pancreatic Cancer" (7 trials) and "Multiple Myeloma" (6 trials). Many other conditions were trialed in "Charleston Hematology Oncology Associates, Pa" in a lesser frequency.

Most popular intervention types in "Charleston Hematology Oncology Associates, Pa" are "Drug" (139 trials), "Other" (22 trials), "Biological" (18 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Docetaxel" (12 trials), "Nivolumab" (11 trials), "Laboratory Biomarker Analysis" (10 trials) and "placebo" (9 trials). Other intervention names were less common.

The vast majority of trials in "Charleston Hematology Oncology Associates, Pa" are 126 trials for "All" genders, 14 trials for "Male" genders and 11 trials for "Female" genders.

Currently, there are NaN active trials in "Charleston Hematology Oncology Associates, Pa". undefined are not yet recruiting, 19 are recruiting, 22 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 72 completed trials in Charleston Hematology Oncology Associates, Pa, undefined suspended trials, and 26 terminated clinical trials to date.

Out of the total trials that were conducted in Charleston Hematology Oncology Associates, Pa, 7 "Phase 1" clinical trials were conducted, 64 "Phase 2" clinical trials and 75 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 0 trials that are defined as “Not Applicable".